ESMO

TILs May Predict Survival in Early HER2-Positive Breast Cancer Treated With Herceptin

September 14th 2024, 10:22pm

Article

High TILs may predict which patients with early HER2-positive breast cancer may have a reduced risk for disease relapse or death with Herceptin treatment.

Lenvima Regimen Offers Benefits in Intermediate Stage Liver Cancer

September 14th 2024, 9:51pm

Article

Patients with intermediate-stage liver cancer may benefit from receiving a Lenvima-Keytruda combination with transarterial chemoembolization.

Survival, Progression Improves With Xofigo Plus Xtandi for Certain Patients With Prostate Cancer

September 14th 2024, 9:40pm

Article

Patients with metastatic, castration-resistant prostate cancer saw significant benefits from the combination of Xofigo and Xtandi.

Keytruda Plus Chemoradiotherapy May Represent New Standard of Care in Cervical Cancer Subset

September 14th 2024, 9:11pm

Article

Patients with previously untreated, high-risk locally advanced cervical cancer experienced improved survival when treated with Keytruda plus chemoradiotherapy.

Postsurgical Keytruda Plus Chemo May Benefit Patients With dMMR Endometrial Cancer

September 14th 2024, 8:30pm

Article

Study findings were mixed regarding the postsurgical combination of Keytruda and chemotherapy with or without radiation among patients with high-risk endometrial cancer.

Rybrevant Plus Chemo Results in Superior Outcomes in EGFR-Mutant Advanced NSCLC

September 14th 2024, 4:34pm

Article

Rybrevant plus chemotherapy improved overall survival versus chemo alone in EGFR-mutant advanced non-small cell lung cancer after disease progression.

Enhertu Demonstrates Overall, Intracranial Activity in HER2-Positive Breast Cancer

September 13th 2024, 10:00pm

Article

Patients with HER2-positive breast cancer benefitted from treatment with Enhertu regardless of brain metastasis.

Welireg Shows Stable Survival Benefits Over Afinitor in Kidney Cancer

September 13th 2024, 9:00pm

Article

Among patients with previously treated advanced clear cell renal cell carcinoma (RCC) Welireg continued to show some benefits, though not to overall survival.

Imfinzi After Primary Treatment Does Not Improve Disease-Free Survival in PD-L1-Positive NSCLC

September 13th 2024, 7:00pm

Article

Patients with NSCLC did not see a disease-free survival benefit with Imfinzi after surgery compared with taking a placebo.

Velcade and Rituxan Help Improve Responses in Marginal Zone Lymphoma

November 24th 2023, 2:00pm

Article

A treatment combination that includes Velcade and Rituxan helps improve responses and the safety profile in marginal zone lymphoma, according to a phase 2 trial.